Maverix Biomics CEO To Present At 13th Annual Biotechnology Industry Organization (BIO) Investor Forum
WHAT: Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual BIO Investor Forum features leading private and emerging public companies.
WHO: Dave Mandelkern, President and co-founder of Maverix Biomics, Inc.
WHY: High throughput genetic sequencing is dramatically changing both scientific and clinical research. Mandelkern will discuss how the Maverix Analytic Platform is helping researchers explore the combination of DNA (genotyping) and RNA (gene expression) data resulting from genetic sequencing studies and how this information is utilized to identify potential pathways and biomarkers, and develop next generation clinical diagnostics for various conditions and diseases.
WHEN: 11:30 a.m., Tuesday October 7, 2014
WHERE: The Sea Cliff Room at the Palace Hotel in San Francisco, California
About the Maverix Analytic Platform
The Maverix Analytic Platform is a cloud-based solution designed for use directly by life sciences and clinical researchers who may not have software or bioinformatics expertise. It leverages proven, open-source algorithms and applications developed at leading research centers. Running in a highly scalable environment that can handle thousands of samples and petabytes of data, the Maverix Analytic Platform is also HIPAA compliant. After loading sequence data from any organism (human, animal, plant, or microbe), researchers are able to immediately perform analysis with reliable, scientifically recommended configurations, as cited in peer- reviewed journal publications, without having to make extensive investments in IT infrastructure. Visualization is provided through a variety of integrated graphical tools, including the UCSC Genome Browser, the world’s most widely used genome browser.
About Maverix Biomics
Based in San Mateo, CA and backed by leading venture capital firms and Silicon Valley investors, Maverix Biomics, Inc. provides researchers with a highly scalable cloud-based platform to manage, analyze, and visualize genomic data, build Communities of Discovery, and place their data in context with the latest public data from the full spectrum of life, including human, plant, animal, or microbial organisms. For more information, visit www.maverixbio.com
About the BIO Investor Forum
The 13th Annual BIO Investor Forum is an international investor conference focused on private and emerging public biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and established biotechnology companies. For more information, visit www.bio.org/events/conferences/13th-annual-bio-investor-forum
WHO: Dave Mandelkern, President and co-founder of Maverix Biomics, Inc.
WHY: High throughput genetic sequencing is dramatically changing both scientific and clinical research. Mandelkern will discuss how the Maverix Analytic Platform is helping researchers explore the combination of DNA (genotyping) and RNA (gene expression) data resulting from genetic sequencing studies and how this information is utilized to identify potential pathways and biomarkers, and develop next generation clinical diagnostics for various conditions and diseases.
WHEN: 11:30 a.m., Tuesday October 7, 2014
WHERE: The Sea Cliff Room at the Palace Hotel in San Francisco, California
About the Maverix Analytic Platform
The Maverix Analytic Platform is a cloud-based solution designed for use directly by life sciences and clinical researchers who may not have software or bioinformatics expertise. It leverages proven, open-source algorithms and applications developed at leading research centers. Running in a highly scalable environment that can handle thousands of samples and petabytes of data, the Maverix Analytic Platform is also HIPAA compliant. After loading sequence data from any organism (human, animal, plant, or microbe), researchers are able to immediately perform analysis with reliable, scientifically recommended configurations, as cited in peer- reviewed journal publications, without having to make extensive investments in IT infrastructure. Visualization is provided through a variety of integrated graphical tools, including the UCSC Genome Browser, the world’s most widely used genome browser.
About Maverix Biomics
Based in San Mateo, CA and backed by leading venture capital firms and Silicon Valley investors, Maverix Biomics, Inc. provides researchers with a highly scalable cloud-based platform to manage, analyze, and visualize genomic data, build Communities of Discovery, and place their data in context with the latest public data from the full spectrum of life, including human, plant, animal, or microbial organisms. For more information, visit www.maverixbio.com
About the BIO Investor Forum
The 13th Annual BIO Investor Forum is an international investor conference focused on private and emerging public biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and established biotechnology companies. For more information, visit www.bio.org/events/conferences/13th-annual-bio-investor-forum